BioSpace News Archive

Forecast to 2030,’ thoroughly examines the Osteomyelitis Treatment industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Postpartum Depression industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Pruritus Treatment industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Systemic Lupus Erythematosus industry to provide essential data & information for the targeted readers.

Vaxxinity, Inc. Chief Executive Officer Mei Mei Hu will participate as a speaker at the White House Summit on the Future of COVID-19 Vaccines.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at 4:30 p.m. ET to report its financial results for the second quarter of 2022.

OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2022 after the close of the U.S. financial markets on Thursday, August 4, 2022.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42nd Annual Growth Conference, which takes place August 8-11, 2022, in Boston at the InterContinental Boston Hotel. Ron Rocca, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will present on Thursday, August 11th, at 12:00 PM ET.

GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), announced that the company will release its financial results for the second quarter of fiscal year 2022 on August 15, 2022 after 4:00 p.m. (ET), followed by a conference call/live audio webcast to discuss the results at 5:00 p.m. (ET).

Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it intends to offer and sell $250 million of American Depositary Shares (“ADSs”), each representing two ordinary shares, in an underwritten public offering.